CN119632921A - 用于儿科患者的生物药物组合物和方法 - Google Patents

用于儿科患者的生物药物组合物和方法 Download PDF

Info

Publication number
CN119632921A
CN119632921A CN202411850626.1A CN202411850626A CN119632921A CN 119632921 A CN119632921 A CN 119632921A CN 202411850626 A CN202411850626 A CN 202411850626A CN 119632921 A CN119632921 A CN 119632921A
Authority
CN
China
Prior art keywords
asthma
eosinophilic
antibody
present disclosure
severe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411850626.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·阿兹米
J·斯坦费尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of CN119632921A publication Critical patent/CN119632921A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202411850626.1A 2017-06-06 2018-05-08 用于儿科患者的生物药物组合物和方法 Pending CN119632921A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762515641P 2017-06-06 2017-06-06
US62/515641 2017-06-06
US201862619206P 2018-01-19 2018-01-19
US62/619206 2018-01-19
PCT/US2018/031518 WO2018226339A1 (en) 2017-06-06 2018-05-08 Biopharmaceutical compositions and methods for pediatric patients
CN201880051204.4A CN110913887A (zh) 2017-06-06 2018-05-08 用于儿科患者的生物药物组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880051204.4A Division CN110913887A (zh) 2017-06-06 2018-05-08 用于儿科患者的生物药物组合物和方法

Publications (1)

Publication Number Publication Date
CN119632921A true CN119632921A (zh) 2025-03-18

Family

ID=64566261

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411850626.1A Pending CN119632921A (zh) 2017-06-06 2018-05-08 用于儿科患者的生物药物组合物和方法
CN201880051204.4A Pending CN110913887A (zh) 2017-06-06 2018-05-08 用于儿科患者的生物药物组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880051204.4A Pending CN110913887A (zh) 2017-06-06 2018-05-08 用于儿科患者的生物药物组合物和方法

Country Status (7)

Country Link
US (2) US11390671B2 (https=)
EP (1) EP3634467A4 (https=)
JP (2) JP7295038B2 (https=)
CN (2) CN119632921A (https=)
BR (1) BR112019025736A2 (https=)
CA (1) CA3064859A1 (https=)
WO (1) WO2018226339A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025736A2 (pt) * 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
AU2020251627A1 (en) * 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
CA3199805A1 (en) * 2020-12-22 2022-06-30 Daren J AUSTIN Interleukin 5 binding protein dosage regimen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
AU633034B2 (en) 1988-11-03 1993-01-21 Schering Corporation Method of preventing or reducing eosinophilia
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
HUT67943A (en) 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US5858089A (en) 1997-08-26 1999-01-12 Martinovic; Zoran Corn buttering tool
DE69838338T2 (de) 1997-10-22 2008-05-21 Jens Rochester Ponikau Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
JP4597643B2 (ja) 2004-11-24 2010-12-15 富士フイルム株式会社 電子内視鏡
DK2152290T3 (da) 2007-04-30 2014-08-18 Glaxosmithkline Llc Fremgangsmåder til indgivelse af anti-il-5-antistoffer
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
JP5035153B2 (ja) 2008-07-14 2012-09-26 市光工業株式会社 車両用灯具
JP6125436B2 (ja) * 2011-02-09 2017-05-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 凍結乾燥製剤
EA201391489A1 (ru) 2011-04-07 2014-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
KR20180037275A (ko) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
BR112019025736A2 (pt) * 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue

Also Published As

Publication number Publication date
US12286472B2 (en) 2025-04-29
US20200157206A1 (en) 2020-05-21
US11390671B2 (en) 2022-07-19
US20220380451A1 (en) 2022-12-01
CN110913887A (zh) 2020-03-24
BR112019025736A2 (pt) 2020-06-30
EP3634467A1 (en) 2020-04-15
WO2018226339A1 (en) 2018-12-13
JP2023113883A (ja) 2023-08-16
EP3634467A4 (en) 2021-07-28
JP7295038B2 (ja) 2023-06-20
JP2020522524A (ja) 2020-07-30
CA3064859A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
US12454571B2 (en) Biopharmaceutical compositions
US12286472B2 (en) Biopharmaceutical compositions and methods for pediatric patients
CN117018190A (zh) 生物制药组合物和相关方法
HK40096185A (zh) 生物医药组合物
BR122024020400A2 (pt) Composição e uso de uma composição
HK40080447A (en) Biopharmaceutical compositions
EA046656B1 (ru) Антигенсвязывающие белки, которые связываются с il-5 и используются для лечения заболеваний

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination